IP Library Granted Patent US 8,178,094
Granted Patent B2
US 8,178,094 · App. 12/809,554 · Granted May 15, 2012

Methods for inhibiting tumor growth or reducing metastatic burden in a subject by administering FDF03 antibodies

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,178,094
App. No.
12/809,554
Granted
May 15, 2012
Kind
B2
Abstract

The present invention relates to methods for identifying and using modulators of FDF03 biological activity in vitro and in vivo that are useful in the treatment of cancer.

Claims (14)

1. A method for inhibiting tumor growth in a subject having colon cancer, comprising administering to the subject an effective amount of an agonist antibody or partial-agonist antibody or antibody fragment thereof specific for the FDF03 inhibitory receptor.

2. The method of claim 1 , wherein the antibody is a humanized, fully human or chimeric antibody.

3. The method of claim 1 , wherein the tumor is a primary or a metastatic tumor.

4. The method of claim 1 , wherein the subject is a human.

5. A method for reducing metastatic burden in a subject having colon cancer, comprising administering to the subject an effective amount of an agonist antibody or partial-agonist antibody, or antibody fragment thereof specific for the FDF03 inhibitory receptor.

6. The method of claim 5 , wherein the antibody is a humanized, fully human or chimeric antibody.

7. The method of claim 5 , wherein the subject is a human.

8. A method for inhibiting tumor growth in a subject having breast cancer, comprising administering to the subject an effective amount of an antibody or antibody fragment thereof that binds to the FDF03 inhibitory receptor and to the FDF03 activating receptor.

9. The method of claim 8 , wherein the antibody is a humanized, fully human or chimeric antibody.

10. The method of claim 8 , wherein the tumor is a primary or a metastatic tumor.

11. The method of claim 8 , wherein the subject is a human.

12. A method for reducing metastatic burden in a subject having breast cancer, comprising administering to the subject an effective amount of an antibody or antibody fragment thereof that binds to the FDF03 inhibiting receptor and to the FDF03 activating receptor.

13. The method of claim 12 , wherein the antibody is a humanized, fully human or chimeric antibody.

14. The method of claim 12 , wherein the subject is a human.

Assignments (2)
MERGER Recorded Aug 8, 2022
From: MERCK SHARP & DOHME CORP.
To: MERCK SHARP & DOHME LLC
Reel/Frame 061102/0145 →
CHANGE OF NAME Recorded Aug 30, 2012
From: SCHERING CORPORATION
To: MERCK SHARP & DOHME CORP.
Reel/Frame 028884/0151 →